Dr Anita J. Chavan

Luxembourg · Deeptech & life sciences

Dr Anita J. Chavan

PhD neuroscientist working in clinical governance and deeptech commercialisation. For over ten years I have moved science towards the market: R&D portfolios, regulatory submissions, venture creation and the partnerships that bring a product to patients and customers.

Deeptech commercialisation Technology valorisation & TRL/CRL Venture creation & spin-off coaching EMA/FDA regulatory submissions R&D grant proposals B2B partnerships & IP
10+ yrsventure development, clinical and R&D roles across the EU, APAC and the US
€10M+R&D and innovation portfolios across research and industry projects
40+regulatory and clinical documents for EMA and FDA submissions
35+strategic B2B agreements: NDAs, MTAs, JDAs, MOUs

Roles I'm interested in

Innovation & valorisation

Technology transfer, venture building and spin-off programmes at universities, RTOs and innovation agencies.

Business development

Partnerships and commercial growth in biotech, medtech, CROs and deeptech scale-ups.

R&D programme leadership

Running multi-project RDI portfolios and EU-funded collaborative programmes.

Experience

2025 – now

Founder & Principal Consultant

M3TRL Consulting, Luxembourg

  • First business creation in Luxembourg: obtained the business permit from the Ministry of the Economy and launched an advisory practice for healthcare, life-science and deeptech ventures.
  • Awarded the Ministry of the Economy's first-time business start-up aid (aide à la primo-création d'entreprise) to establish M3TRL Consulting.
  • Market access research for a healthcare company: structured interviews with 20+ general practitioners, clinical leads and diagnostic heads to shape product positioning and pricing.
  • Non-dilutive funding for an early-stage company: grant writing, co-facilitated regional resilience workshops, technical reporting and early regulatory compliance groundwork.
  • Advises biotech and deeptech ventures on go-to-market strategy, business planning and IP structuring.
2023 – 2024

R&D Commercialisation Expert · Technology Valorisation

University of Luxembourg

  • Led market-entry analysis and commercialisation strategy for a biogenic alternative to microplastics (FNR-JUMP): market segments, pricing models and go-to-market path.
  • Coached entrepreneurial researchers through venture creation, producing the business and financial plan with the technology transfer office and business development advisors.
  • Authored an FNR-CORE proposal on cancer therapeutics, advancing ductal carcinoma studies with novel biomarkers.
2022 – 2023

Group Program Manager

Shiok Meats (cell-based agritech), Singapore

  • Directed 15+ R&D and innovation projects worth €5M+, raising operational efficiency by 20% through a successful merger.
  • Negotiated and executed 35+ strategic agreements (NDAs, MTAs, JDAs, MOUs) with 60 colleagues across legal, business development, R&D and marketing.
  • Structured and prosecuted a four-patent portfolio with patent attorneys, contributing to a 30% increase in company valuation.
2020 – 2022

Medical Writer · Scientific & Clinical Consultant

Novotech CRO

  • Authored 40+ regulatory and clinical documents for EMA and FDA submissions, all approved on first submission, for biotech, medtech and pharmaceutical sponsors.
  • Assessed commercial viability and protocol feasibility for multi-centre trial portfolios worth €15M+, cutting regulatory query cycles by 35%.
  • Aligned 25+ external stakeholders (key opinion leaders, sponsor executives, hospital sites), saving sponsors an estimated €450k+ in trial delays and refiling. Novostar Award 2022, Employee of the Year 2020.
2018 – 2019

Research Fellow · Translational Scientist

Institute of Bioengineering and Nanotechnology (IBN), A*STAR, Singapore

  • Built an AI-integrated in-vitro screening platform with 80% predictive accuracy, a commercial IP asset for pre-clinical safety testing.
  • Worked with the US EPA and bioinformatics teams on regulatory compliance frameworks and documentation towards FDA acceptance.
2017 – 2018

Research Fellow · Preclinical Translation

Worcester Polytechnic Institute, Massachusetts, USA

  • Led pre-clinical drug screening protocols using microfluidic and high-precision imaging platforms to validate neuroprotective drug effects.
2015 – 2017

Research Fellow · R&D Project Lead

University of Arizona, Tucson, USA

  • Directed a $750k oncology R&D project on Ras oncogene pathways, leading a team of six to deliver every scientific milestone on schedule.
2010 – 2015

PhD Researcher · Assistant Lecturer

La Trobe University, Melbourne, Australia

  • Directed three collaborative life-science projects and supervised three PhD students, alongside teaching.
  • Invited speaker, International Batten Disease Conference, Argentina, 2014.

Education & certificates

2015

PhD in Neuroscience

La Trobe University, Australia · Life sciences and innovative model development for rare genetic disease

2009

MSc in Life Sciences

University of Mumbai, India · Microbiology, genetics and environmental science

2007

BSc in Zoology

University of Mumbai, India · Developmental biology, genetics and ecology

Training

Entrepreneurship programmes

House of Entrepreneurship Luxembourg: Bloom training programme · Harvard Online (edX): Technology Entrepreneurship, Lab to Market · Commercialization Reactor (Latvia): deeptech venture creation

Awards

Scholarships & honours

Australian Postgraduate Research Scholarship, La Trobe Full Fee Scholarship and JN Tata Endowment Scholarship (2010) · Novostar Award (2022) and Employee of the Year (2020), Novotech CRO

Ecosystem & governance

Selected publications

  1. Chavan AJ. Nanomaterials for cancer theranostics: clinical trial process, market statistics, and factors to increase success rate from lab to clinic. Springer book chapter, 2022.
  2. Varma VB, Chavan AJ. Magnetic droplets for advanced theranostics: cancer diagnosis, targeted delivery and therapeutics. Springer book chapter, 2022.
  3. Khanna A, Lotfi P, Chavan AJ, et al. The small GTPases Ras and Rap1 bind to and control TORC2 activity. Scientific Reports, 2016.
  4. Annesley SJ, Chen S, Francione LM, Sanislav O, Chavan AJ, et al. Dictyostelium, a microbial model for brain disease. Biochim Biophys Acta, 2014.

Contact

Based in Luxembourg. I work in English, Hindi and Marathi, and I am learning French and Luxembourgish to work with local partners in their own languages.

dr.chavan@m3trl.com